Literature DB >> 2380887

Partial cystectomy in the management of rhabdomyosarcoma of the bladder: a report from the Intergroup Rhabdomyosarcoma Study.

D M Hays1, W Lawrence, W M Crist, E Wiener, R B Raney, A Ragab, M Tefft, B Webber, J Johnston, H M Maurer.   

Abstract

Among 154 children with primary vesical rhabdomyosarcoma entered in the IRS (1972 to 1986), tumor excision constituting a partial cystectomy was performed in 33. These procedures were performed in the following situations (1) as an initial operation for localized disease (22); (2) as a secondary procedure for localized disease following chemotherapy (CT) or CT/irradiation response (6); and (3) as an initial operation in the presence of disseminated abdominal disease (5). Partial cystectomy included full-thickness resection of 15% to 80% of the bladder wall. Ureters were reimplanted or revised in two patients. The 33 patients undergoing partial cystectomy were in the following clinical groups: I, total excision (10); II, gross excision with "microscopic residual" or positive nodes (8); III, subtotal excision (10); and IV, tumor dissemination (5). Patients in clinical groups I and II received vincristine and actinomycin-D (VA) or VA + cyclophosphamide (VAC) +/- adriamycin (ADR). Patients in groups III and IV received the same agents +/- cisplatin. Irradiation (2,000 to 5,000 cGy) was administered to 18 patients (55%) in groups II to IV. Six relapses occurred among 28 patients with localized disease, and one among five patients with dissemination; all resulting in progressive disease and/or death. Estimated 3-year survival following partial cystectomy (79%) is similar to that for all patients with primary bladder tumors (78%). In contrast with the total group, in which the majority of survivors have eventually required total cystectomy; 25 of 26 survivors of partial cystectomy have functional bladders from 146 to 686 weeks (median, 356 weeks) from study entry.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1990        PMID: 2380887     DOI: 10.1016/s0022-3468(05)80004-1

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  7 in total

1.  A comparison of MyoD1 and fetal acetylcholine receptor expression in childhood tumors and normal tissues: implications for the molecular diagnosis of minimal disease in rhabdomyosarcomas.

Authors:  S Gattenloehner; B Dockhorn-Dworniczak; I Leuschner; A Vincent; H K Müller-Hermelink; A Marx
Journal:  J Mol Diagn       Date:  1999-11       Impact factor: 5.568

2.  Primary tumor size predicts pathologic findings in the retroperitoneal lymph nodes in patients with paratesticular rhabdomyosarcoma.

Authors:  Shaheen Alanee; Bradley Holland; Danuta Dynda; Onsi Kamel; Sabha Ganai
Journal:  Virchows Arch       Date:  2014-10-08       Impact factor: 4.064

3.  Surgery in rhabdomyosarcoma of the bladder, prostate and vagina.

Authors:  M Fisch; R Bürger; U Barthels; P Gutjahr; R Hohenfellner
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

4.  Gross perianal embryonal rhabdomyosarcoma with severe multiple bone metastases throughout the body: a case report.

Authors:  Jing-Jing Lu; Min-Bin Chen; Xiao-Jiao Gao; Yan Zhang; Yuan-Yuan Liu; Yang Yong; Ping Li
Journal:  J Int Med Res       Date:  2022-03       Impact factor: 1.671

5.  Conservative surgery in multimodal therapy for pelvic rhabdomyosarcoma in children.

Authors:  A Atra; H C Ward; K Aitken; M Boyle; C Dicks-Mireaux; P G Duffy; C D Mitchell; P N Plowman; P G Ransley; J Pritchard
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

6.  Bladder and kidney function after cure of pelvic rhabdomyosarcoma in childhood.

Authors:  C K Yeung; H C Ward; P G Ransley; P G Duffy; J Pritchard
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

7.  Demographics, stage distribution, and relative roles of surgery and radiotherapy on survival of persons with primary prostate sarcomas.

Authors:  Jonathan D Tward; Matthew M Poppe; Ying J Hitchcock; Brock O'Neil; Daniel J Albertson; Dennis C Shrieve
Journal:  Cancer Med       Date:  2018-11-19       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.